Inspira Technologies Validates Next-Gen Standalone HYLA(TM) Blood Sensor with Clinical-Grade Accuracy, Targeting $48 Billion Heart-Lung Surgery Market

Stock Information for Inspira Technologies Oxy B.H.N. Ltd.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Inspira Technologies Oxy B.H.N. Ltd.

Inspira Receives Nasdaq Notification Regarding Minimum Market Value Deficiency
Inspira Expands U.S. Commercial Footprint: Deploys ART100 at a New Premier New York Academic Medical Center, Ranked Top 10 in New York State
Inspira Accelerates U.S. Commercial Strategy: FDA-Cleared ART100 Targets Market Adoption at AmSECT 2026 via Glo-Med Networks
Inspira Technologies Announces Receipt of Nasdaq Notification Regarding Minimum Bid Price Requirement
Inspira Secures Vendor Approval from $12 Billion Revenue HMO (World's 2nd Largest), Enabling Immediate ART100 Deployment
Inspira Announces Pricing of $4.75 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market under Nasdaq Rules
ART100 Becomes Inspira's First System to Complete Clinical Evaluation and Enters Budgeted Procurement at Top U.S. Medical Center
Inspira Advances to Final Governmental Budgetary Validation Procedures for Previously Announced Binding Purchase Orders

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.